

ASPEN PHARMACARE HOLDINGS LIMITED
(Incorporated in the Republic of South Africa) (“Aspen Holdings”)
Registration number: 1985/002935/06
Share code: APN
ISIN: ZAE000066692
LEI: 635400ZYSN1IRD5QWQ94
and its subsidiaries (collectively “Aspen”)

ASPEN CONFIRMS NON-BINDING TERM SHEET ON MANUFACTURE AND SALE OF AN ASPEN BRANDED COVID-19 VACCINE THROUGHOUT AFRICA AND WITHDRAWAL OF CAUTIONARY

With reference to the cautionary announcement dated 29 November 2021, Aspen is pleased to confirm that one of its wholly owned South African subsidiaries, Aspen SA Operations (Pty) Limited (“Aspen SA”), has confirmed a non-binding term sheet with Janssen Pharmaceuticals, Inc. and Janssen Pharmaceutica NV, two of the Janssen Pharmaceutical Companies of Johnson & Johnson (“Johnson & Johnson”), that will form the basis for negotiation of a definitive agreement on the manufacture and sale of an Aspen branded COVID-19 vaccine throughout Africa. That agreement would expand the existing technical transfer and manufacturing agreements between the parties to grant Aspen SA the rights to:

- (i) manufacture finished SARS-CoV-2 COVID-19 vaccine product from drug substance supplied by Johnson & Johnson; and
- (ii) sell the finished form vaccine under Aspen branding to public sector markets in Africa through transactions with designated multilateral organisations and with national governments of member states of the African Union.

In addition, Johnson & Johnson would grant Aspen a license to the enabling intellectual property for this purpose. Aspen SA plans to launch this vaccine under the brand name “Aspenovax”.

The term of the grant of rights and supply of drug substance, subject to the signing of the definitive agreement, would be until 31 December 2026. The non-binding term sheet contemplates a good faith undertaking between the parties to discuss the expansion of the agreement to include any new versions of the drug substance, such as those developed for new variants or as a different formulation for administration as a booster, and the applicable terms thereof.

Following the above confirmation, shareholders are advised that caution is no longer required to be exercised when dealing in the Company’s securities.

A media broadcast webinar to further discuss this matter has been scheduled to start at 15:30 (SAST) today, 30 November 2021. The details for this webinar are as follows:

Webinar ID: 990 9930 8622 | **Passcode:** 104435 | **Webinar link:**

<https://aspenpharma.zoom.us/j/99099308622?pwd=SEJwYnQyYkZYTB2R290R1hKRkpxdz09>

Q&As limited to questions posted via the webinar link.

Durban
30 November 2021

Sponsor
Investec Bank Limited